Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

182 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-21

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single-center, self-controlled, evaluator-blinded prospective study, which applies pressurized gloves and foot caps to prevent paclitaxel-induced peripheral neuropathy in patients with nasopharyngeal carcinoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Simple Surgical Glove Compression to Prevent Chemotherapy-Induced Peripheral Neuropathy

NCT07169864

Breast Cancer Chemotherapy Induced Peripheral Neuropathy (CIPN) Neoadjuvant Therapy

NOT_YET_RECRUITING NA

Chemotherapy - Induced Peripheral Neuropathy

NCT05138042

Breast Cancer Female

COMPLETED NA

Explored About Temperature Packing Care to Improve the Quality of Life for Chemotherapy Induced Peripheral Neuropathy (CIPN) in Colorectal Cancer and Gastric Cancer Patient

NCT06205173

Colorectal Cancer Gastric Cancer Chemotherapy-induced Peripheral Neuropathy

COMPLETED NA

Glove Compression for Chemotherapy-Induced Neuropathy

NCT07105553

Chemotherapy-induced Peripheral Neuropathy (CIPN) Gynecologic Cancers Ovarian Cancer (OvCa) +1 more

COMPLETED NA

Compression Gloves to Reduce Albumin-binding Paclitaxel Induced Peripheral Sensory and Motor Neurotoxicity (REMAINING)

NCT04446819

Peripheral Neuropathy

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nasopharyngeal Carcinoma CIPN - Chemotherapy-Induced Peripheral Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The Account and IWRS end of the clinical trial randomization system of Sun Yat-sen University Cancer Center (SYSUCC) randomly determined the limb (left or right) of the participants to receive intervention, and the hand and foot on the same side were classified into the same group during the randomization process.

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Evaluator blind design was adopted, and all evaluations were made after the participants had received the intervention and withdrawn the intervention. At this time, the blinded evaluator did not know the tribal groups, while both the participants and researchers knew the trial groups.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Participants wear pressurized gloves and foot caps for 15 minutes before their chemotherapy treatment, during the treatment, and for 15 minutes after it ended.

Group Type EXPERIMENTAL

Pressurized gloves and foot caps

Intervention Type OTHER

Using pressurized gloves and foot caps in order to prevent chemotherapy-induced peripheral neuropathy (CIPN).

Group B

No intervention was done before and after chemotherapy with paclitaxels.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pressurized gloves and foot caps

Using pressurized gloves and foot caps in order to prevent chemotherapy-induced peripheral neuropathy (CIPN).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age range from 18 to 70
* ECOG physical status score: 0-2
* Newly diagnosed patients who have not received antitumor therapy
* Nasopharyngeal carcinoma confirmed by pathology
* Paclitaxel is included in the chemotherapy regimen
* Laboratory examination results within one week before enrollment should meet the following conditions: neutrophils (ANC) ≥1.5×109/L, platelets (PLT) ≥80×109/L, total bilirubin (TBI) ≤1.5× upper limit of normal value (2mg/ dL), ALT and AST ≤2× upper limit of normal value
* Patients voluntarily participate and provide written informed consent

Exclusion Criteria

* Patients with peripheral neuropathy, hand-foot syndrome, and dermatomyositis
* Patients with missing fingers or toes
* Patients with Raynaud's syndrome and peripheral vascular ischemia
* Pregnant or lactating women
* Those considered unsuitable for inclusion by the researcher

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No